已收盤 09-20 16:00:00 美东时间
-0.110
-3.43%
Benchmark analyst Robert Wasserman downgrades Codexis (NASDAQ:CDXS) from Buy to Hold.
08-19 21:47
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务,助力上市公司传播ESG理念,提升ESG可持续发展表现。点击查看【 ESG评级中...
07-22 07:00
Codexis (NASDAQ:CDXS) said it has finalized a sales agreement with Crosswalk Therapeutics for its gene therapy programs for Fabry and Pompe disease that were discontinued by partner Takeda (TAK) in Ap...
07-02 05:28
Codexis-Eligible to Receive Future Development,Commercial Milestone Payments in...
07-02 04:07
Codexis Finalizes Purchase Agreement With Crosswalk Therapeutics for Gene Thera...
07-02 04:05
Gainers: Zscaler (ZS) +15%. Ambarella (AMBA) +14%. OmniAb (OABI) +4%. Intellia Therapeutics (NTLA) +4%. Summit Therapeutics (SMMT) +3%. Losers: MongoDB (MDB) -22%. OneMedNet (ONMD) -5%. Datadog (DDO...
05-31 05:10
David Iben put it well when he said, 'Volatility is not a risk we care about. W...
05-05 21:39